Intervention of Air Pollution and Acute Coronary Syndrome

Acute Coronary Syndrome Clinical Trial

Official title:

Intervention of Air Pollution and Acute Coronary Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04126434
• Other study ID #: WeiHuang19
• Status: Recruiting
• Phase: N/A
• Start date: April 10, 2019
• Est. completion date: December 31, 2022

Study information

• Verified date: September 2021
• Source: Peking University
• Contact: Wei Huang, PhD
• Phone: +86-13521966787
• Email: whuang[@]bjmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine the effect of intervention of ambient air pollution on acute coronary syndrome patients.

Description:

To investgate the effect of wearing facemasks to decreasing levels of exposure to ambient air on acute coronary syndrome patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Non-smoker of any type during past six months and living in a non-smoking household.

2. A diagnosis of myocardial infarction or unstable angina 7-90 days prior to signed informed consent.

Exclusion Criteria:

1. Unstable CV disorders including uncompensated heart failure, refractory angina, uncontrolled arrhythmias, critical valvular heart disease and severe hypertension.

2. A history of infection with human immunodeficiency virus.

3. History of malignancy including leukemia and lymphoma AND/OR any severe, life-threatening disease AND/OR history of drug abuse within the last 2 years.

4. Pregnancy or intent to get pregnant during the study period.

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Syndrome

Intervention

Device:
• mask
facemask

Locations

Country	Name	City	State
China	Peking University ,School of Public Health	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	vascular function	Systolic blood pressure and diastolic blood pressure measured by omron HBP-1300	six months
Primary	autonomic nervous function	Twenty four-hour electrocardiograms and heart rate variability	six months